Company Overview
About Accuryn
Accuryn is a critical care hemodynamic monitoring system developed by Retia Medical, a medical device company headquartered in Ann Arbor, Michigan. The Accuryn Monitoring System provides continuous, real-time measurement of cardiac output, stroke volume, and fluid responsiveness in critically ill patients — parameters that are essential for guiding hemodynamic management in the intensive care unit (ICU) but historically required invasive pulmonary artery catheter (PAC) placement to measure. Retia Medical's proprietary pulse contour analysis algorithm enables continuous cardiac output monitoring using standard arterial line waveforms already present in most ICU patients, without requiring additional invasive access.
Business Model & Competitive Advantage
Accuryn has received FDA 510(k) clearance and is commercially available in US hospital ICU and high-acuity settings. The system integrates with existing patient monitors and electronic health record (EHR) systems, providing hemodynamic parameters in a format familiar to intensivists and anesthesiologists. The clinical value proposition centers on enabling individualized, goal-directed fluid therapy — using real-time cardiac output and fluid responsiveness data to guide IV fluid administration decisions — which evidence suggests can reduce complications from both under- and over-resuscitation in septic shock, post-surgical, and other critically ill patient populations.
Competitive Landscape 2025–2026
Retia Medical was founded to commercialize hemodynamic monitoring technology developed at the University of Michigan, with a focus on making advanced cardiac output monitoring accessible and non-invasive. The company has built clinical evidence supporting Accuryn's accuracy versus reference standard thermodilution cardiac output measurement. Accuryn competes with hemodynamic monitoring systems from Edwards Lifesciences (FloTrac/Acumen), LiDCO (now part of Masimo), and Deltex Medical in the non-invasive and minimally invasive cardiac output monitoring segment.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Compare Accuryn with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Accuryn? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Accuryn Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Accuryn vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →